Cargando…

Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study

BACKGROUND: Cocaine and crack use has been associated with HIV and HCV infections, but its consequences on HCV progression have not been well established. We analyzed the impact of cocaine/crack use on liver fibrosis progression in a cohort of HIV-HCV co-infected patients. METHODS: A Canadian multic...

Descripción completa

Detalles Bibliográficos
Autores principales: Martel-Laferrière, Valérie, Nitulescu, Roy, Cox, Joseph, Cooper, Curtis, Tyndall, Mark, Rouleau, Danielle, Walmsley, Sharon, Wong, Leo, Klein, Marina B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240225/
https://www.ncbi.nlm.nih.gov/pubmed/28095797
http://dx.doi.org/10.1186/s12879-017-2196-0
_version_ 1782496025522470912
author Martel-Laferrière, Valérie
Nitulescu, Roy
Cox, Joseph
Cooper, Curtis
Tyndall, Mark
Rouleau, Danielle
Walmsley, Sharon
Wong, Leo
Klein, Marina B.
author_facet Martel-Laferrière, Valérie
Nitulescu, Roy
Cox, Joseph
Cooper, Curtis
Tyndall, Mark
Rouleau, Danielle
Walmsley, Sharon
Wong, Leo
Klein, Marina B.
author_sort Martel-Laferrière, Valérie
collection PubMed
description BACKGROUND: Cocaine and crack use has been associated with HIV and HCV infections, but its consequences on HCV progression have not been well established. We analyzed the impact of cocaine/crack use on liver fibrosis progression in a cohort of HIV-HCV co-infected patients. METHODS: A Canadian multicenter prospective cohort study followed 1238 HIV-HCV co-infected persons every 6 months between 2003 and 2013. Data were analyzed from 573 patients with positive HCV RNA, not on HCV treatment, without significant liver fibrosis (AST-to-Platelet Ratio Index (APRI) <1.5) or history of end-stage liver disease at baseline, and having at least two study visits. Recent cocaine/crack use was defined as use within 6 months of cohort entry. Incidence rates of progression to significant fibrosis (APRI ≥ 1.5) were determined according to recent cocaine/crack use. Cox Proportional Hazards models were used to assess the association between time-updated cocaine/crack use and progression to APRI ≥ 1.5 adjusting for age, sex, HCV duration, baseline ln(APRI), and time-updated alcohol abuse, history of other drug use and CD4+ cell count. RESULTS: At baseline, 211 persons (37%) were recent cocaine/crack users and 501 (87%) ever used cocaine/crack. Recent users did not differ from non-recent users on gender, age, and CD4+ T-cell count. Over 1599 person-years of follow up (522 PY in recent users, 887 PY in previous users and 190 PY in never users),158 (28%) persons developed significant fibrosis (9.9/100 PY; 95% CI, 8.3–11.4); 56 (27%) recent users (10.7/100 PY; 7.9–13.5), 81 (28%) previous users (9.1/100 PY; 7.1–11.1), and 21 (29%) never users (11.1/100 PY; 6.3–15.8). There was no association between ever having used or time-updated cocaine/crack use and progression to APRI ≥ 1.5 (adjusted HR (95%CI): 0.96 (0.58, 1.57) and 0.88;(0.63–1.25), respectively). CONCLUSIONS: We could not find evidence that cocaine/crack use is associated with progression to advanced liver fibrosis in our prospective study of HIV-HCV co-infected patients.
format Online
Article
Text
id pubmed-5240225
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52402252017-01-19 Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study Martel-Laferrière, Valérie Nitulescu, Roy Cox, Joseph Cooper, Curtis Tyndall, Mark Rouleau, Danielle Walmsley, Sharon Wong, Leo Klein, Marina B. BMC Infect Dis Research Article BACKGROUND: Cocaine and crack use has been associated with HIV and HCV infections, but its consequences on HCV progression have not been well established. We analyzed the impact of cocaine/crack use on liver fibrosis progression in a cohort of HIV-HCV co-infected patients. METHODS: A Canadian multicenter prospective cohort study followed 1238 HIV-HCV co-infected persons every 6 months between 2003 and 2013. Data were analyzed from 573 patients with positive HCV RNA, not on HCV treatment, without significant liver fibrosis (AST-to-Platelet Ratio Index (APRI) <1.5) or history of end-stage liver disease at baseline, and having at least two study visits. Recent cocaine/crack use was defined as use within 6 months of cohort entry. Incidence rates of progression to significant fibrosis (APRI ≥ 1.5) were determined according to recent cocaine/crack use. Cox Proportional Hazards models were used to assess the association between time-updated cocaine/crack use and progression to APRI ≥ 1.5 adjusting for age, sex, HCV duration, baseline ln(APRI), and time-updated alcohol abuse, history of other drug use and CD4+ cell count. RESULTS: At baseline, 211 persons (37%) were recent cocaine/crack users and 501 (87%) ever used cocaine/crack. Recent users did not differ from non-recent users on gender, age, and CD4+ T-cell count. Over 1599 person-years of follow up (522 PY in recent users, 887 PY in previous users and 190 PY in never users),158 (28%) persons developed significant fibrosis (9.9/100 PY; 95% CI, 8.3–11.4); 56 (27%) recent users (10.7/100 PY; 7.9–13.5), 81 (28%) previous users (9.1/100 PY; 7.1–11.1), and 21 (29%) never users (11.1/100 PY; 6.3–15.8). There was no association between ever having used or time-updated cocaine/crack use and progression to APRI ≥ 1.5 (adjusted HR (95%CI): 0.96 (0.58, 1.57) and 0.88;(0.63–1.25), respectively). CONCLUSIONS: We could not find evidence that cocaine/crack use is associated with progression to advanced liver fibrosis in our prospective study of HIV-HCV co-infected patients. BioMed Central 2017-01-17 /pmc/articles/PMC5240225/ /pubmed/28095797 http://dx.doi.org/10.1186/s12879-017-2196-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Martel-Laferrière, Valérie
Nitulescu, Roy
Cox, Joseph
Cooper, Curtis
Tyndall, Mark
Rouleau, Danielle
Walmsley, Sharon
Wong, Leo
Klein, Marina B.
Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
title Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
title_full Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
title_fullStr Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
title_full_unstemmed Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
title_short Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
title_sort cocaine/crack use is not associated with fibrosis progression measured by ast-to-platelet ratio index in hiv-hcv co-infected patients: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240225/
https://www.ncbi.nlm.nih.gov/pubmed/28095797
http://dx.doi.org/10.1186/s12879-017-2196-0
work_keys_str_mv AT martellaferrierevalerie cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT nitulescuroy cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT coxjoseph cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT coopercurtis cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT tyndallmark cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT rouleaudanielle cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT walmsleysharon cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT wongleo cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT kleinmarinab cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy
AT cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy